Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users

Abstract

The major route of hepatitis C virus (HCV) transmission in the United States is injection drug use. We hypothesized that if an HCV vaccine were available, vaccination could affect HCV transmission among people who inject drugs by reducing HCV titers after viral exposure without necessarily achieving sterilizing immunity. To investigate this possibility, we developed a mathematical model to determine transmission probabilities relative to the HCV RNA titers of needle/syringe-sharing donors. We simulated sharing of two types of syringes fitted with needles that retain either large or small amounts of fluid after expulsion. Using previously published viral kinetics data from both naïve subjects infected with HCV and reinfected individuals who had previously cleared an HCV infection, we estimated transmission risk between pairs of serodiscordant injecting drug users, accounting for syringe type, rinsing, and sharing frequency. We calculated that the risk of HCV transmission through syringe sharing increased ~10-fold as viral titers (log IU/ml) increased ~25-fold. Cumulative analyses showed that, assuming sharing episodes every 7 days, the mean transmission risk over the first 6 months was >90% between two people sharing syringes when one had an HCV RNA titer >5 log IU/ml. For those with preexisting immunity that rapidly controlled HCV, the cumulative risk decreased to 1 to 25% depending on HCV titer and syringe type. Our modeling approach demonstrates that, even with transient viral replication after exposure during injection drug use, HCV transmission among people sharing syringes could be reduced through vaccination if an HCV vaccine were available.

Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago

“…Re-treatment, which can reduce/eradicate viral titers as many as seven times for the same person (Fig. 1C,D), is predicted to be highly efficacious to curtail transmission (i.e., reducing incidence) in agreement with our recent modeling predictions [8]. An unbiased DAA scale-up of 5% (or 50 per 1000 PWID) per year is projected to achieve the WHO target of 90% incidence reduction by 2030 ( Fig.…”

<p>SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions</p>

“…7 In addition to the above, a newly described therapeutic strategy is to inhibit the Notch signaling pathway that appears to have a profibrotic role in development of NAFLD. 12 To the best of our knowledge, none of the available studied therapeutics has been approved by the FDA; 13 however, pioglitazone, Glucagon Like Peptide-1 (GLP-1) receptor agonists (GLP-1RA), and Vitamin E are considered reasonable options given their positive effect on NAFLD. 14 Sodium glucose cotransporter-2 inhibitors (SGLT2i(s)) that, similar to GLP-1RA, were initially introduced as glycemialowering agents were found to have beneficial effects on cardiovascular, renal, and metabolic outcomes, including NAFLD.…”

Hepatitis C Vaccine: 10 Good Reasons for Continuing

“…Even a vaccine only decreasing viral load in IVDUs following infection would significantly decrease the epidemic in this population. ( 30 ) Unfortunately, no studies have yet been performed to model the benefits of an HCV vaccine in low‐income countries with different modes of contamination.…”